The genitourinary cancer multi-disciplinary treatment team was founded in 2005, with top experts in the field of urology, radiation oncology, medical oncology, pathology, radiology and nuclear medicine. Based on accurate diagnosis and pathological tumor grading & staging, the team is dedicated to improve the survival and quality of life through cutting-edge integrated therapies, including surgery, chemotherapy, radiotherapy, endocrinal therapy, interventional therapy, biological therapy and targeted therapy. The number of genitourinary cancers treated by this team has long come out at the top of China. Furthermore, Shanghai Anti-Cancer Association prostate cancer center and Fudan University prostate cancer treatment and research center were both affiliated to this team.

In the past five years, the team has taken part in 23 domestic and international multi-centric prospective clinical trials, and played a leading role in ten of the trials. Meanwhile, a total of five top prizes have been awarded to the team, including the first prize of Shanghai Science and Technology Development, the first prize of College Science and Technology Development, the second prize of Chinese Medical Science and Technology and the second prize of Shanghai Medical Science and Technology. The team members, either as first author or corresponding author, published more than 160 peer-reviewed papers, some of which were published in international famous journals, such as Cancer Cell, JCB, PNAS, JCO, EU and highly appreciated by editors from Faculty 1000 and Nature Reviews Urology. Moreover, the research achievements of the team were cited and recommended by the EAU guideline. The chair of the team, Professor Dingwei Ye of urology is also the vice chair of genitourinary cancer committee of Chinese Anti-Cancer Association , Shanghai Urological Association, and editorial board of Chinese edition of NCCN Clinical Practice Guidelines in Kidney Cancer. He is also a member as a decisive reviewer of Natural Science Foundation of China(NSFC) and member of American Society of Clinical Oncology(ASCO), International Society of Urology (SIU) Collaboration Advisory Committee and International Society of Urologic Disease(ICUD). In addition, Prof Dingwei Ye is a reviewer or member of editorial board of many international or domestic journals, including European Urology, Journal of Cellular and Molecular Medicine, Cancer Investigation, British Journal of Dermatology ,Chinese Urological Journal, Clinical Oncological Journal, etc. He has also been awarded as one of the Leading Talents in Shanghai Medicine and one of the Outstanding Academic Leaders in Shanghai.